Cytokinetics (CYTK) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $63.74 +2.29%
Revenue Growth %: +2,004.1%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +2,004.1%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.36), $0.13 worse than the analyst estimate of ($1.23). Revenue for the quarter came in at $463 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
- Popular stocks with increasing option volume: INTC SPCX RIOT PLTR CRWV NFLX SMCI SOFI IREN HOOD
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
